

UNITED STATES PATENT AND TRADEMARK OFFICE

UNITED STATES DEPARTMENT OF COMMERCE
United States Patent and Trademark Office
Address: COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231
www.uspto.gov

APPLICATION NO.	FILING DATE	FIRST NAMED INVENTOR	ATTORNEY DOCKET NO.	CONFIRMATION NO.
09/623,611	10/06/2000	Gregory Coia	674537-2002	3929

20999 7590 06/27/2002
FROMMER LAWRENCE & HAUG
745 FIFTH AVENUE- 10TH FL.
NEW YORK, NY 10151

RECEIVED
JUL 29 2002
TECH CENTER 1600/2900

EXAMINER

PONNALURI, PADMASHRI

ART UNIT PAPER NUMBER

1627


DATE MAILED: 06/27/2002

13

Please find below and/or attached an Office communication concerning this application or proceeding.

JUL - 1 A 10:20
FROMMER LAWRENCE
& HAUG, LLP

DOCKETED



UNITED STATES DEPARTMENT OF COMMERCE
Patent and Trademark Office
COMMISSIONER OF PATENTS AND TRADEMARKS
Washington, D.C. 20231

SERIAL NUMBER	FILING DATE	FIRST NAMED APPLICANT	ATTORNEY DOCKET NO.
09/623,611	10/6/00		

RECEIVED
JUL 29 2002
TECH CENTER 1600/2900

EXAMINER	
P. Ponnaluri	
ART UNIT	PAPER NUMBER
1627	13

DATE MAILED:

Please find below a communication from the EXAMINER in charge of this application
Commissioner of Patents

The communication filed on **4/26/02** is not fully responsive to the communication mailed **2/26/02**. **See the attached Raw Sequence Listing Error Report.**

Since the response appears to be bona fide, but through an apparent oversight or inadvertence failed to provide a complete response, applicant is given **ONE (1) MONTH or THIRTY (30) DAYS** from the mailing date of this notice, whichever is longer, within which to supply the omission or correction in order to avoid abandonment. EXTENSIONS OF THIS TIME PERIOD MAY BE GRANTED UNDER 37 CFR 1.136(a).

PLEASE NOTE: A reply to a notice to comply with the sequence rules should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office.

Please direct all replies to the United States Patent and Trademark Office via one (1) of the following:

1. Electronically submitted through EFS-Bio
(<http://www.uspto.gov/ebs/efs/downloads/documents.htm>), EFS
Submission User Manual - ePAVE)

2. Mailed to:
U.S. Patent and Trademark Office
Box Sequence, P.O. Box 2327
Arlington, VA 22202

3. Mailed by Federal Express, United Parcel Service or other delivery service to:
U. S. Patent and Trademark Office
2011 South Clark Place
Customer Window, Box Sequence
Crystal Plaza Two, Lobby, Room 1B03
Arlington, Virginia 22202



RECEIVED

JUL 29 2002

TECH CENTER 1600/2000

4. Hand Carried directly to the Customer Window at:
2011 South Clark Place
Crystal Plaza Two, Lobby, Room 1B03, Box Sequence,
Arlington, Virginia 22202

Any inquiry concerning this communication should be directed to P. Ponnaluri whose telephone number is (703) 305-3884. The examiner can normally be reached on Monday through Friday from 8:00 am to 4:30 pm.

If attempts to reach the examiner by telephone are unsuccessful, the examiner's supervisor, Jyothsna Venkat, can be reached at (703)308-2439. The fax number for this group is (703)305-3014.

Any inquiry of a general nature or relating to the status of this application or proceeding should be directed to the group receptionist whose telephone number is (703)308-0196.

P. Ponnaluri
Patent Examiner
Technology center 1600
Art Unit 1627
25 June 2002


PADMASHRI PONNALURI
PRIMARY EXAMINER

Application No.: 09/623,614

**NOTICE TO COMPLY WITH REQUIREMENTS FOR PATENT APPLICATIONS CONTAINING
NUCLEOTIDE SEQUENCE AND/OR AMINO ACID SEQUENCE DISCLOSURES**

The nucleotide and/or amino acid sequence disclosure contained in this application does not comply with the requirements for such a disclosure as set forth in 37 C.F.R. 1.821 - 1.825 for the following reason(s):

- ☒ 1. This application clearly fails to comply with the requirements of 37 C.F.R. 1.821-1.825. Applicant's attention is directed to these regulations, published at 1114 OG 29, May 15, 1990 and at 55 FR 18230, May 1, 1990.
- ☐ 2. This application does not contain, as a separate part of the disclosure on paper copy, a "Sequence Listing" as required by 37 C.F.R. 1.821(c).
- ☐ 3. A copy of the "Sequence Listing" in computer readable form has not been submitted as required by 37 C.F.R. 1.821(e).
- ☒ 4. A copy of the "Sequence Listing" in computer readable form has been submitted. However, the content of the computer readable form does not comply with the requirements of 37 C.F.R. 1.822 and/or 1.823, as indicated on the attached copy of the marked -up "Raw Sequence Listing."
- ☐ 5. The computer readable form that has been filed with this application has been found to be damaged and/or unreadable as indicated on the attached CRF Diskette Problem Report. A Substitute computer readable form must be submitted as required by 37 C.F.R. 1.825(d).
- ☐ 6. The paper copy of the "Sequence Listing" is not the same as the computer readable form of the "Sequence Listing" as required by 37 C.F.R. 1.821(e).
- ☐ 7. Other:

Applicant Must Provide:

- ☒ An initial or substitute computer readable form (CRF) copy of the "Sequence Listing".
- ☒ An initial or substitute paper copy of the "Sequence Listing", as well as an amendment directing its entry into the specification.
- ☒ A statement that the content of the paper and computer readable copies are the same and, where applicable, include no new matter, as required by 37 C.F.R. 1.821(e) or 1.821(f) or 1.821(g) or 1.825(b) or 1.825(d).

For questions regarding compliance to these requirements, please contact:

For Rules Interpretation, call (703) 308-4216

For CRF Submission Help, call (703) 308-4212

PatentIn Software Program Support (SIRA)


Technical Assistance.....703-287-0200

To Purchase PatentIn Software.....703-306-2600

PLEASE RETURN A COPY OF THIS NOTICE WITH YOUR RESPONSE



BIOTECHNOLOGY
SYSTEMS
BRANCH



RECEIVED
MAY 24 2002
TECH CENTER 1600/2900

RAW SEQUENCE LISTING ERROR REPORT

The Biotechnology Systems Branch of the Scientific and Technical Information Center (STIC) detected errors when processing the following computer readable form:

Application Serial Number: 09/623,611A
Source: 1609
Date Processed by STIC: 5/14/2002

#12
RECEIVED

JUL 29 2002
TECH CENTER 1600/2900

THE ATTACHED PRINTOUT EXPLAINS DETECTED ERRORS.

PLEASE FORWARD THIS INFORMATION TO THE APPLICANT BY EITHER:

- 1) INCLUDING A COPY OF THIS PRINTOUT IN YOUR NEXT COMMUNICATION TO THE APPLICANT, WITH A NOTICE TO COMPLY or,
- 2) TELEPHONING APPLICANT AND FAXING A COPY OF THIS PRINTOUT, WITH A NOTICE TO COMPLY

FOR CRF SUBMISSION QUESTIONS, PLEASE CONTACT MARK SPENCER, 703-308-4212.

FOR SEQUENCE RULES INTERPRETATION, PLEASE CONTACT ROBERT WAX, 703-308-4216.

PATENTIN 2.1 e-mail help: patin21help@uspto.gov or phone 703-306-4119 (R. Wax)

PATENTIN 3.0 e-mail help: patin3help@uspto.gov or phone 703-306-4119 (R. Wax)

TO REDUCE ERRORED SEQUENCE LISTINGS, PLEASE USE THE CHECKER
VERSION 3.1 PROGRAM, ACCESSIBLE THROUGH THE U.S. PATENT AND
TRADEMARK OFFICE WEBSITE. SEE BELOW FOR ADDRESS:

<http://www.uspto.gov/web/offices/pac/checker>

Applicants submitting genetic sequence information electronically on diskette or CD-Rom should be aware that there is a possibility that the disk/CD-Rom may have been affected by treatment given to all incoming mail.

Please consider using alternate methods of submission for the disk/CD-Rom or replacement disk/CD-Rom.

Any reply including a sequence listing in electronic form should NOT be sent to the 20231 zip code address for the United States Patent and Trademark Office, and instead should be sent via the following to the indicated addresses:

1. EFS-Bio (<<http://www.uspto.gov/efb/efs/downloads/documents.htm>> , EFS Submission User Manual - ePAVE)
2. U.S. Postal Service: U.S. Patent and Trademark Office, Box Sequence, P.O. Box 2327, Arlington, VA 22202
3. Hand Carry directly to:
U.S. Patent and Trademark Office, Technology Center 1600, Reception Area, 7th Floor, Examiner Name,
Sequence Information, Crystal Mall One, 1911 South Clark Street, Arlington, VA 22202
Or
U.S. Patent and Trademark Office, Box Sequence, Customer Window, Lobby, Room 1B03, Crystal Plaza Two,
2011 South Clark Place, Arlington, VA 22202
4. Federal Express, United Parcel Service, or other delivery service to: U.S. Patent and Trademark Office,
Box Sequence, Room 1B03-Mailroom, Crystal Plaza Two, 2011 South Clark Place, Arlington, VA 22202

Revised 01/29/2002



RAW SEQUENCE LISTING
PATENT APPLICATION: US/09/623,611A

DATE: 05/14/2002
TIME: 15:50:03

Input Set : A:\00064205.txt
Output Set: N:\CRF3\05142002\I623611A.raw

Does Not Comply
Corrected Diskette Needed

pp 1-2

3 <110> APPLICANT: Coia, et al.
5 <120> TITLE OF INVENTION: V-like Domain Binding Molecules
7 <130> FILE REFERENCE: 674537-2002
9 <140> CURRENT APPLICATION NUMBER: 09/623,611A
10 <141> CURRENT FILING DATE: 2000-10-06
12 <150> PRIOR APPLICATION NUMBER: PCT/AU99/00136
13 <151> PRIOR FILING DATE: 1999-03-05
15 <150> PRIOR APPLICATION NUMBER: AU PP 2210
16 <151> PRIOR FILING DATE: 1998-03-06
18 <160> NUMBER OF SEQ ID NOS: 142
20 <170> SOFTWARE: PatentIn version 3.0

RECEIVED

JUL 2 9 2002

TECH CENTER 1600/2900

ERRORED SEQUENCES

262 <210> SEQ ID NO: 18
263 <211> LENGTH: 66
264 <212> TYPE: DNA
265 <213> ORGANISM: Artificial Sequence
267 <220> FEATURE:
268 <223> OTHER INFORMATION: oligonucleotide for CDR2 haemagglutinin tag
270 <400> SEQUENCE: 18
E--> 271 gaagtctgtg cggcaacctta cccgtatgac gttccggact acgcctaga tgattccatc
273 tgcacg
609 <210> SEQ ID NO: 37
610 <211> LENGTH: (67) 68 *shown*
611 <212> TYPE: DNA
612 <213> ORGANISM: Artificial Sequence
614 <220> FEATURE:
615 <223> OTHER INFORMATION: oligonucleotide for CDR2 randomisation
617 <220> FEATURE:
618 <221> NAME/KEY: misc_feature
619 <222> LOCATION: (1)..(67)
620 <223> OTHER INFORMATION: nucleotide 'n' can be any nucleotide 'a', 'c', 'g', or 't'.
622 <220> FEATURE:
623 <221> NAME/KEY: misc_feature
624 <222> LOCATION: (1)..(67)
625 <223> OTHER INFORMATION: 'k' is 'g' or 't'
628 <400> SEQUENCE: 37
E--> 629 gtgactgaagt ctgtgcggca acctacnnkn nkgggnnkga gttgaccttc ctagatgatt
E--> 631 ccatctg
671 <210> SEQ ID NO: 40
672 <211> LENGTH: (29) 30 (*see p. 2*)

(61) 60
66

(60) 61
(67) 68

RAW SEQUENCE LISTING

PATENT APPLICATION: US/09/623,611A

DATE: 05/14/2002

TIME: 15:50:03

Input Set : A:\00064205.txt

Output Set: N:\CRF3\05142002\I623611A.raw

673 <212> TYPE: DNA

674 <213> ORGANISM: Artificial Sequence

676 <220> FEATURE:

677 <223> OTHER INFORMATION: oligonucleotide for CDR2 randomisation

679 <400> SEQUENCE: 40

E--> 680 gtagcatgcccg cacagacttc agtcacctg

2372 <210> SEQ ID NO: 142

2373 <211> LENGTH: 6

E--> 2374 <212> TYPE: Artificial Sequence

2375 <213> ORGANISM: CDR1 and CDR3 inserts possessing randomly generated sequence

2377 <400> SEQUENCE: 142

2379 SPECQD

2380 1

(29)30

<2127> this mandatory numeric identifier and response are missing

if this is an amino acid sequence, use three-letter amino acids, and number the amino acids under every 5 amino acids

insert <2207

and <2237> explanation goes on this line (do not use TAB codes between amino acids)

FBI

Use of n and/or Xaa has been detected in the Sequence Listing. Review the Sequence Listing to insure a corresponding explanation is presented in the <220> to <223> fields of each sequence using n or Xaa.

VERIFICATION SUMMARY

DATE: 05/14/2002


PATENT APPLICATION: US/09/623,611A

TIME: 15:50:04

Input Set : A:\00064205.txt

Output Set: N:\CRF3\05142002\I623611A.raw

L:1703 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:97 after pos.:0
L:1706 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:97 after pos.:16
L:1725 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:98 after pos.:0
L:1728 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:98 after pos.:16
L:1747 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:99 after pos.:0
L:1766 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:100 after pos.:0
L:1769 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:100 after pos.:16
L:1788 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:101 after pos.:0
L:2033 M:341 W: (46) "n" or "Xaa" used, for SEQ ID#:117 after pos.:0
L:2374 M:310 E: (3) Wrong or Missing Sequence Type, TYPE:



SEQUENCE LISTING

RECEIVED
JUL 29 2002
TECH CENTER 1600/2900

<10> DIATECH PTY, LTD
Coia, Gregory
Galanis, Maria
Hudson, Peter John
Irving, Robert Alexander
Nuttall, Stewart Douglas

<120> V-Like Binding Molecules

<130> 674537-2002

<140> 09/623,611

<141> 2000-10-06

<160> 142

<170> PatentIn version 3.1

<210> 1

<211> 6

<212> PRT

<213> Homo Sapiens

<220>

<221> UNSURE

<222> (1)..(6)

<223> conserved sequence in CDR3-like surface loop

<400> 1

Met Tyr Pro Pro Pro Tyr

1

5

<210> 2

<211> 54

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide for 5' CTLA-4 amplification

<400> 2

ttattactcg cggcccagcc ggccatggcc gcaatgcacg tggcccagcc tgct

54

<210> 3

<211> 60

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide for 5' CTLA-4 amplification

<400> 3
ttattactcg cggcccagcc ggccatggcc gcaatgcacg tggcccagcc tgctgtggta 60

<210> 4
<211> 45
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for 5' CTLA-4 amplification

<400> 4
tctcacagtg cacaggcaat gcacgtggcc cagcctgctg tggtta 45

<210> 5
<211> 39
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for 5' CTLA-4 amplification

<400> 5
tctcacagtg cacaggcaat gcacgtggcc cagcctgct 39

<210> 6
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for 5' CTLA-4 amplification

<400> 6
gcccagccgg ccgaattcgc aatgcacgtg gccagcctg ct 42

<210> 7
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for 5' CTLA-4 amplification

<400> 7
gcagctaata cgactcacta taggaacaga ccaccatgga cgtggcccag cctgctgtgg 60

<210> 8
<211> 42
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for 3' CTLA-4 amplification

<400> 8
atctgcgggcc gctacataaa tctgggtacc gttgccgatg cc 42

<210> 9
<211> 66
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for 3' CTLA-4 amplification

<400> 9
gctgaattct gatcagtgat ggtgatggtg atgtgcgggc gcgtcagaat ctgggcacgg 60
ttcttg 66

<210> 10
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for 3' CTLA-4 amplification

 <400> 10
gcccttgggc cgggagatgg tctgcttcag tggcgagggc aggtctgtgt g 51

<210> 11
<211> 49
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for 3' CTLA-4 amplification

<400> 11
cgagggcagg tctgtgtggg tcacggtgca cgtgaacctc tccccggag 49

<210> 12
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for 3' CTLA-4 amplification

<400> 12
cgtgaacctc tccccggagt tccagtcac ctcgcagatg ctggcctcac c 51

<210> 13
<211> 84
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR1- somatostatin

<400> 13
agctttgtgt gtgagtatgc agctggctgc aagaatttct tctggaagac tttcacatcc 60
tgtgccactg aggtccgggt gaca 84

<210> 14
<211> 84
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR3- somatostatin

<400> 14
ctgggtaccg ttgccgatgc cacaggatgt gaaagtcttc cagaagaaat tcttcagacc 60
agcctccacc ttgcagatgt agag 84

<210> 15
<211> 75
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR1- som- randomisation

<220>
<221> misc_feature
<222> (1)..(75)
<223> "n" can be a,t,g or c

<220>
<221> misc_feature
<222> (1)..(75)
<223> "k" is g or t

<400> 15
agctttgtgt gtgagtatgc agctggctgc aagaatnnkn nknnknnknn knnkacatcc 60
tgtgccactg aggtc 75

<210> 16
<211> 75
<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide for CDR3- som- randomisation

<220>

<221> misc_feature

<222> (1)..(75)

<223> "n" can be a,t,g or c

<220>

<221> misc_feature

<222> (1)..(75)

<223> "m" is a or c

<400> 16

ctgggtaccg ttgccgatgc cacaggatgt mnnmnnmnnm nnnnnmnnat tcttcagcc 60

agcctccacc ttgca 75

<210> 17

<211> 21

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide for CDR2 haemagglutinin tag

<400> 17

gtaggttgcc gcacagactt c 21

<210> 18

<211> 66

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide for CDR2 haemagglutinin tag

<400> 18

gaagtctgtg cggcaaccta cccgtatgac gttccggact acgccctaga tgattccatc 60

tgcacg 66

<210> 19

<211> 78

<212> DNA

<213> Artificial Sequence

<220>

<223> Oligonucleotide for CDR-1 anti-lysozyme

<400> 19
gccagctttg tgtgtgagta tgccagtggc tacaccatcg ggccgtactg catgggcgtc 60
cgggtgacag tgcttcgg 78

<210> 20
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-2 anti-lysozyme

<400> 20
tgtgcggcag ccatcaacat gggcgggtggc atcaccttcc tagatgattc catctgcacg 60

<210> 21
<211> 60
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-2 anti-lysozyme

<400> 21
atctaggaag gtgatgccac cgcccatggt gatgggtgcc gcacagactt cagtcacctg 60

<210> 22
<211> 69
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-3 anti-lysozyme

<400> 22
cagcccgtgg ccgcactcgt agtaggacgc gtagatcgtc gagtccacct tgcagatgta 60
gagtcccgt 69

<210> 23
<211> 72
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-3 anti-lysozyme

<400> 23
aatctgggta ccgttgccga tgccggagtc atagccgtac cctcccgtgg acagcccgtg 60
gccgcactcg ta 72

<210> 24
<211> 78
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-1 anti-melanoma

<400> 24
gccagctttg tgtgtgagta tgccagtgga ttcaccttca gttcctacgc catgtccgtc 60
cgggtgacag tgcttcgg 78

<210> 25
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-2 anti-melanoma

<400> 25
gccatctccg gatccggagg ctgacctac ctagatgatt ccatctgcac g 51

<210> 26
<211> 54
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-2 anti-melanoma

<400> 26
gtaggctcag cctccgcatc cggagatggc tgccgcacag acttcagtca cctg 54

<210> 27
<211> 69
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-3 anti-melanoma

<400> 27
cacgtccatg tagtagtctc cctcctcgcc ggcagtcgcc cagcccacct tgcagatgta 60
gagtcccgt 69

<210> 28
<211> 51
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-3 anti-melanoma

<400> 28
aatctgggta ccgttgccga tgcccacgtc catgtagtag tctccctcct c 51

<210> 29
<211> 66
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-1 randomisation

<220>
<221> misc_feature
<222> (1)..(66)
<223> "n" can be a,c,t or g

<220>
<221> misc_feature
<222> (1)..(66)
<223> "k" can be 'g' or 't'

<400> 29
agctttgtgt gtgagtatgc annknnknnk nnknnknnkn nknnkgccac tgaggtccgg 60
gtgaca 66

<210> 30
<211> 68
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR1 randomisation

<400> 30
cacgtggccc agcctgctgt ggtactggcc agcagccgag gcatcgccag ctttgtgtgt 60
gagtatgc 68

<210> 31
<211> 66
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR1 randomisation

<220>

<221> misc_feature
<222> (1)..(66)
<223> "n" can be a,t,g or c

<220>
<221> misc_feature
<222> (1)..(66)
<223> "s" can be g or c

<400> 31
gtgtgtgagt acgcgtncnn snnnsnnsnns nnsnnstgcn nsgctactga gggttcgtgtg 60
accgtc 66

<210> 32
<211> 73
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR1 randomisation

<220>
<221> misc_feature
<222> (25)..(26)
<223> "X" can be a,t,g or c

ND/
<220>
<221> misc_feature
<222> (28)..(29)
<223> "X" can be a,t,g or c

<220>
<221> misc_feature
<222> (31)..(32)
<223> "X" can be a,t,g or c

<220>
<221> misc_feature
<222> (34)..(38)
<223> "X" can be a,t,g or c

<220>
<221> misc_feature
<222> (40)..(41)
<223> "X" can be a,t,g or c

<220>
<221> misc_feature

<222> (43)..(44)
<223> "X" can be a,t,g or c

<400> 32
gccagcttttg tgtgtgagta tgcannknnk nnknnknnkn nknnkggcgt ccgggtgaca 60
gtgcttcggc agg 73

<210> 33
<211> 82
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR1 randomisation

<220>
<221> misc_feature
<222> (1)..(82)
<223> "n" can be a,c,t or g

<220>
<221> misc_feature
<222> (1)..(82)
<223> "k" can be t or g

D/ <400> 33
gccagcttttg tgtgtgagta tgcannknnk nnknnknnkn nknnknnktg cnnkggcgtc 60
cgggtgacag tgcttcggca gg 82

<210> 34
<211> 82
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR1 randomisation

<220>
<221> misc_feature
<222> (1)..(82)
<223> "n" can be a,t g or c

<220>
<221> misc_feature
<222> (1)..(82)
<223> "k" can be g or t

<400> 34

gccagctttg tgtgtgagta tgcannknnk ywynnkywyn nknnkywytg cnnkggcgtc 60
cgggtgacag tgcttcggca gg 82

<210> 35
<211> 70
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR1 randomisation

<220>
<221> misc_feature
<222> (1)..(70)
<223> "n" can be a,c,t or g

<220>
<221> misc_feature
<222> (1)..(70)
<223> "k" can be t or g

<220>
<221> misc_feature
<222> (1)..(70)
<223> "w" can be t or a

<220>
<221> misc_feature
<222> (1)..(70)
<223> "t" can be t or c

<220>
<221> misc_feature
<222> (1)..(70)
<223> "k" can be t or g

<400> 35
gccagctttg tgtgtgagta tgcattctcca ggcnnknnkn nknnkgtccg ggtgacagtg 60
cttcggcagg 70

<210> 36
<211> 70
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR1 randomisation

<220>
<221> misc_feature
<222> (1)..(70)
<223> "n" can be a,t,g or c

<220>
<221> misc_feature
<222> (1)..(70)
<223> "k" can be g or t

<400> 36
gccagctttg tgtgtgagta tgcattctcca gccnnktgcn nknnkgtccg ggtgacagtg 60
cttcggcagg 70

<210> 37
<211> 68
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-2 randomisation

<220>
<221> misc_feature
<222> (1)..(67)
<223> "n" can be a,c,t or g

<220>
<221> misc_feature
<222> (1)..(67)
<223> "k" can be t or g

<400> 37
gtgactgaag tctgtgcggc aacctacnnk nnkggggnkg agttgacctt cctagatgat 60
tccatctg 68

<210> 38
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-2 randomisation

<400> 38
gtaggttgcc gcacagactt cagtcacctg 30

<210> 39

<211> 68
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-2 randomisation

<220>
<221> misc_feature
<222> (1)..(68)
<223> "n" can be a,t,g or c

<220>
<221> misc_feature
<222> (1)..(68)
<223> "k" can be g or t

<400> 39
gtgactgaag tctgtgcggc atgctacnnk nnkggggnkg agttgacctt cctagatgat 60
tccatctg 68

<210> 40
<211> 30
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-2 randomisation

<400> 40
gtagcatgcc gcacagactt cagtcacctg 30

<210> 41
<211> 69
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR-3 randomisation

<220>
<221> misc_feature
<222> (1)..(69)
<223> "n" can be a,t,g or c

<220>
<221> misc_feature
<222> (1)..(69)
<223> "m" can be a or c


<400> 41
ctgggtaccg ttgccgatgc cmnnmnnmnn mnnmnnmnnm nnnmnnmnnct ccaccttgca 60
gatgtagag 69

<210> 42
<211> 67
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR3 randomisation

<220>
<221> misc_feature
<222> (1)..(67)
<223> "n" can be a,c,t or g

<220>
<221> misc_feature
<222> (1)..(67)
<223> "s" can be c or g

 <400> 42
aggtggaann snnsnnsnns nnsnnstgcn nsnnnsnnnn snnsnnsnns ggcacggca 60
acggtac 67

<210> 43
<211> 78
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR3 randomisation

<220>
<221> misc_feature
<222> (1)..(78)
<223> "n" can be a,t, g or c

<220>
<221> misc_feature
<222> (1)..(78)
<223> "m" can be a or c

<400> 43
aatctgggta ccgttgccga tgccmnnmnn mnnmnnmnnm nnnmnnmnnm mnnncacctt 60
gcagatgtag agtcccgt 78

<210> 44
<211> 93
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR3 randomisation

<220>
<221> misc_feature
<222> (29)..(30)
<223> "x" can be a,t,g or c

<220>
<221> misc_feature
<222> (32)..(33)
<223> "x" can be a,t,g or c

<220>
<221> misc_feature
<222> (35)..(36)
<223> "x" can be a,t,g or c

2/
<220>
<221> misc_feature
<222> (38)..(39)
<223> "x" can be a,t,g or c

<220>
<221> misc_feature
<222> (41)..(42)
<223> "x" can be a,t,g or c

<220>
<221> misc_feature
<222> (44)..(45)
<223> "x" can be a,t,g or c

<220>
<221> misc_feature
<222> (48)..(48)
<223> "x" can be a,t,g or c

<220>
<221> misc_feature
<222> (50)..(51)
<223> "x" can be a,t,g or c


<220>
<221> misc_feature
<222> (53)..(54)
<223> "x" can be a,t,g or c

<220>
<221> misc_feature
<222> (56)..(57)
<223> "x" can be a,t,g or c

<220>
<221> misc_feature
<222> (59)..(60)
<223> "x" can be a,t,g or c

<220>
<221> misc_feature
<222> (62)..(63)
<223> "x" can be a,t,g or c

<220>
<221> misc_feature
<222> (65)..(66)
<223> "x" can be a,t,g or c

 <220>
<221> misc_feature
<222> (47)..(47)
<223> "x" can be a,t,g or c

<400> 44
aatctgggta ccgttgccga tgcccagmnn mnnnnnnnnnn nnnnnnnnnn nnnnnnnnnn 60
nnnnnnctcc accttgccga ttagaggtcc cgt 93

<210> 45
<211> 81
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR3 randomisation

<220>
<221> misc_feature
<222> (1)..(81)
<223> "n" can be a,t,g or c

<220>

<221> misc_feature
<222> (1)..(81)
<223> "m" can be a or c

<400> 45
aatctgggta ccgttgccga tgccmnnmnn mnnmngcam nnnnnmnnnn nnnnnnnncac 60

cttgagatg tagagtcccg t 81

<210> 46
<211> 87
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR3 randomisation

<220>
<221> misc_feature
<222> (1)..(87)
<223> "n" can be a,t,g or c

<220>
<221> misc_feature
<222> (1)..(87)
<223> "m" can be a or c

<400> 46
aatctgggta ccgttgccga tgccmnnmnn mnnmnnmng camnnnnnnnn nnnnnnnnnnn 60

mnnacaccttg cagatgtaga gtcccggt 87

<210> 47
<211> 99
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR3 randomisation

<220>
<221> misc_feature
<222> (1)..(99)
<223> "n" can be a,c,t or g

<220>
<221> misc_feature
<222> (1)..(99)
<223> "m" can be a or c

<400> 47
aatctgggta ccgttgccga tgccmnnmnn mnnmnnmnnm nngcamnnnn nnnnnnnnnn 60
mnnmnnmnnm nnnncacct tgcagatgta gagtcccg 99

<210> 48
<211> 87
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CDR3 randomisation

<220>
<221> misc_feature
<222> (1)..(87)
<223> "n" can be a,t,g or c

<220>
<221> misc_feature
<222> (1)..(87)
<223> "m" can be a or c

<220>
<221> misc_feature
<222> (1)..(87)
<223> "r" can be a or g

<220>
<221> misc_feature
<222> (1)..(87)
<223> "w" can be a or t

<400> 48
aatctgggta ccgttgccga tgccrwrnnn mnnmnnmnnng camnnnnnnn nnnnnnnnnn 60
mnnncacctg cagatgtaga gtcccg 87

<210> 49
<211> 70
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CTLA4 codon change

<400> 49
atgcacgtgg cccagcctgc tgtggtgctg gccagcagcc gtggcatcgc cagctttgtg 60
tgtgaatatg 70

<210> 50
<211> 77
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CTLA4 codon change

<400> 50
gccagctttg tgtgtgaata tgcgtctggc tataccatcg gcccgactg catgggtgtg 60
cgtgtgaccg tgctgcg 77

<210> 51
<211> 54
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CTLA4 codon change

<400> 51
gtgcgtgtga ccgtgctgcg tcaggcggat agccaggtga ccgaagtttg cgcg 54

<210> 52
<211> 75
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CTLA4 codon change

<400> 52
caggtgaccg aagtttgcgc gccagcgatc aacatgggcg gtggcatcac cttcctggat 60
gattccatct gcacc 75

<210> 53
<211> 66
<212> DNA
<213> Artificial Sequence

<220>
<223> Oligonucleotide for CTLA4 codon change

<400> 53
cagaccctgg atggtcaggt tcacctggtt accgctggag gtgccggtgc agatggaatc 60
atccag 66

<210> 54
<211> 57

<212> DNA
 <213> Artificial Sequence

 <220>
 <223> Oligonucleotide for CTLA4 codon change

 <400> 54
 cactttgcag atgtacagac cggtatccat ggcacgcaga ccctggatgg tcagggtt 57

 <210> 55
 <211> 66
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Oligonucleotide for CTLA4 codon change

 <400> 55
 caggccatga ccgcattcgt aataagacgc atagatgggtg ctatccactt tgcagatgta 60

 cagacc 66

 <210> 56
 <211> 69
 <212> DNA
 <213> Artificial Sequence

 <220>
 <223> Oligonucleotide for CTLA4 codon change

 <400> 56
 ctgggtaccg ttgccgatgc cagaatcgta gccatagcca ccggtggaca ggccatgacc 60

 gcattcgta 69

 <210> 57
 <211> 672
 <212> DNA
 <213> Homo Sapiens

 <220>
 <221> CDS
 <222> (109)..(453)
 <223> Polynucleotide encoding Human CTLA-4 cDNA

 <400> 57
 atggcttgcc ttggatttca gcggcacaag gctcagctga acctggctgc caggacctgg 60

 ccctgcactc tectgttttt tcttctcttc atccctgtct tctgcaaa gca atg cac 117
 Ala Met His
 1

 gtg gcc cag cct gct gtg gta ctg gcc agc agc cga ggc atc gcc agc 165

Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly Ile Ala Ser
5 10 15

ttt gtg tgt gag tat gca tct cca ggc aaa gcc act gag gtc cgg gtg 213
Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu Val Arg Val
20 25 30 35

aca gtg ctt cgg cag gct gac agc cag gtg act gaa gtc tgt gcg gca 261
Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val Cys Ala Ala
40 45 50

acc tac atg acg ggg aat gag ttg acc ttc cta gat gat tcc atc tgc 309
Thr Tyr Met Thr Gly Asn Glu Leu Thr Phe Leu Asp Asp Ser Ile Cys
55 60 65

acg ggc acc tcc agt gga aat caa gtg aac ctc act atc caa gga ctg 357
Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile Gln Gly Leu
70 75 80

agg gcc atg gac acg gga ctc tac atc tgc aag gtg gag ctc atg tac 405
Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu Leu Met Tyr
85 90 95

cca ccg cca tac tac ctg ggc ata ggc aac gga acc cag att tat gta 453
Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln Ile Tyr Val
100 105 110 115

attgatccag aaccgtgcc agattctgac ttcctcctct ggatccttgc agcagttagt 513

tcgggggttgt ttttttatag cttttctctc acagctgttt ctttgagcaa aatgctaaag 573

aaaagaagcc ctcttacaac aggggtctat gtgaaaatgc cccaacaga gccagaatgt 633

gaaaagcaat ttcagcctta ttttattccc atcaattga 672

<210> 58
<211> 115
<212> PRT
<213> Homo Sapiens

<400> 58

Ala Met His Val Ala Gln Pro Ala Val Val Leu Ala Ser Ser Arg Gly
1 5 10 15

Ile Ala Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu
20 25 30

Val Arg Val Thr Val Leu Arg Gln Ala Asp Ser Gln Val Thr Glu Val
35 40 45

Cys Ala Ala Thr Tyr Met Thr Gly Asn Glu Leu Thr Phe Leu Asp Asp
50 55 60

Ser Ile Cys Thr Gly Thr Ser Ser Gly Asn Gln Val Asn Leu Thr Ile
65 70 75 80


Gln Gly Leu Arg Ala Met Asp Thr Gly Leu Tyr Ile Cys Lys Val Glu
85 90 95

Leu Met Tyr Pro Pro Pro Tyr Tyr Leu Gly Ile Gly Asn Gly Thr Gln
100 105 110

Ile Tyr Val
115

<210> 59
<211> 7
<212> PRT
<213> Homo Sapiens

<400> 59

 Ser Pro Gly Lys Ala Thr Glu
1 5

<210> 60
<211> 14
<212> PRT
<213> Homo Sapiens

<400> 60

Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr Ser Cys
1 5 10

<210> 61
<211> 9
<212> PRT
<213> Homo Sapiens

<400> 61

Tyr Met Met Gly Asn Glu Leu Thr Phe
1 5

<210> 62
<211> 9
<212> PRT
<213> Homo Sapiens

<400> 62

Leu Met Tyr Pro Pro Pro Tyr Tyr Leu
1 5

<210> 63
<211> 9
<212> PRT
<213> Artificial Sequence

<220>
<223> Haemagglutinin tag

<400> 63

Tyr Pro Tyr Asp Val Pro Asp Tyr Ala
1 5

<210> 64
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> Sequence from anti-lysozyme antibody

<400> 64

Ser Gly Tyr Thr Ile Gly Pro Tyr Cys Met Gly
1 5 10

<210> 65
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> Sequence from anti-lysozyme antibody

<400> 65

Thr Tyr Met Met Gly Asn Glu Leu Thr Phe
1 5 10

<210> 66
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> Sequence from anti-lysozyme antibody

<400> 66

Asp Ser Thr Ile Tyr Ala Ser Tyr Tyr Glu Cys Gly His Gly Leu Ser
1 5 10 15

Thr Gly Gly Tyr Gly Tyr Asp Ser
20

<210> 67
<211> 11
<212> PRT
<213> Homo Sapiens

<400> 67

Ser Gly Phe Thr Phe Ser Ser Tyr Ala Met Ser
1 5 10

<210> 68
<211> 10
<212> PRT
<213> Homo Sapiens

<400> 68

Ala Ile Ser Gly Ser Gly Gly Ser Thr Tyr
1 5 10

<210> 69
<211> 15
<212> PRT
<213> Homo Sapiens

<400> 69

Gly Trp Gly Leu Arg Gly Glu Glu Gly Asp Tyr Tyr Met Asp Val
1 5 10 15

<210> 70
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> Flag tag

<400> 70

Ala Ala Ala Asp Tyr Lys Asp Asp Asp Asp Lys Ala Ala Asp Tyr Lys
1 5 10 15

Asp Asp Asp Asp Lys
20

<210> 71
<211> 14
<212> PRT
<213> Homo Sapiens

<400> 71

Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Lys Ala Thr Glu
1 5 10

<210> 72
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein

<400> 72

Ser Phe Val Cys Glu Tyr Ala Ser Gly Tyr Thr Ile Gly Pro Tyr Cys
1 5 10 15

Met Gly

<210> 73
<211> 24
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein

<400> 73

Ser Phe Val Cys Glu Tyr Ala Ala Gly Cys Lys Asn Phe Phe Trp Lys
1 5 10 15

Thr Phe Thr Ser Cys Ala Thr Glu
20

<210> 74
<211> 18
<212> PRT
<213> Homo Sapiens

<400> 74

Ser Phe Val Cys Glu Tyr Ala Ser Gly Phe Thr Phe Ser Ser Tyr Ala


Met Ser

<210> 75
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> "Xaa" can be any amino acid

 <220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> "Xaa" can be any amino acid

<400> 75

Ser Phe Val Cys Glu Tyr Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Gly
1 5 10 15

<210> 76

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence from fusion protein containing the random sequence

<220>

<221> MISC_FEATURE

<222> (8)..(8)

<223> "Xaa" can be any amino acid

<220>

<221> MISC_FEATURE

<222> (9)..(9)

<223> "Xaa" can be any amino acid

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> "Xaa" can be any amino acid

<220>

<221> MISC_FEATURE

<222> (11)..(11)

<223> "Xaa" can be any amino acid

<220>

<221> MISC_FEATURE

<222> (12)..(12)

<223> "Xaa" can be any amino acid

<220>

<221> MISC_FEATURE

<222> (13)..(13)

<223> "Xaa" can be any amino acid

<220>

<221> MISC_FEATURE

<222> (14)..(14)

<223> "Xaa" can be any amino acid

<220>

<221> MISC_FEATURE
<222> (15)..(15)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> "Xaa" can be any amino acid

<400> 76

Ser Phe Val Cys Glu Tyr Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys
1 5 10 15

Xaa Gly

<210> 77
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (20)..(20)
<223> "Xaa" can be any amino acid

<400> 77

Ser Phe Val Cys Glu Tyr Ala Xaa Xaa Ala Arg Xaa Ala Arg Xaa Xaa
1 5 10 15

Ala Arg Cys Xaa Gly
20

<210> 78
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> "Xaa" can be any amino acid

<400> 78

Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Xaa Xaa Xaa Xaa
1 5 10

<210> 79

<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> "Xaa" can be any amino acid

<400> 79

Ser Phe Val Cys Glu Tyr Ala Ser Pro Gly Xaa Cys Xaa Xaa
1 5 10

<210> 80
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> "Xaa" can be any amino acid

<400> 80

Ser Phe Val Cys Glu Tyr Ala Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Ala
1 5 10 15

Thr Glu

<210> 81
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (9)..(9)

<223> "Xaa" can be any amino acid

<220>

<221> MISC_FEATURE

<222> (10)..(10)

<223> "Xaa" can be any amino acid

<220>

<221> MISC_FEATURE

<222> (11)..(11)

<223> "Xaa" can be any amino acid

<220>

<221> MISC_FEATURE

<222> (12)..(12)

<223> "Xaa" can be any amino acid

<220>

<221> MISC_FEATURE

<222> (13)..(13)

<223> "Xaa" can be any amino acid

<220>

<221> MISC_FEATURE

<222> (15)..(15)

<223> "Xaa" can be any amino acid

<400> 81

Ser Phe Val Cys Glu Tyr Ala Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Ala
1 5 10 15

Thr Glu

<210> 82

<211> 24

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence from fusion protein containing the random sequence

<220>

<221> MISC_FEATURE

<222> (13)..(13)

<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (18)..(18)
<223> "Xaa" can be any amino acid

<400> 82

Ser Phe Val Cys Glu Tyr Ala Ala Gly Cys Lys Asn Xaa Xaa Xaa Xaa
1 5 10 15

Xaa Xaa Thr Ser Cys Ala Thr Glu
20

<210> 83
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein

<400> 83

Gln Val Thr Glu Val Cys Ala Ala Thr Tyr Met Met Gly Asn Glu Leu
1 5 10 15

Thr Phe Leu Asp Asp Ser Ile Cys Thr
20 25

<210> 84
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein

<400> 84

Gln Val Thr Glu Val Cys Ala Ala Ala Ile Asn Met Gly Gly Gly Ile
1 5 10 15

Thr Phe Leu Asp Asp Ser Ile Cys Thr
20 25

<210> 85
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein

<400> 85

Gln Val Thr Glu Val Cys Ala Ala Thr Tyr Pro Tyr Asp Val Pro Asp
1 5 10 15

Tyr Ala Leu Asp Asp Ser Ile Cys Thr
20 25

<210> 86
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein

<400> 86

Gln Val Thr Glu Val Cys Ala Ala Ala Ile Ser Gly Ser Gly Gly Ser
1 5 10 15

Thr Tyr Leu Asp Asp Ser Ile Cys Thr
20 25

<210> 87
<211> 25

<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion sequence containing the random sequence 1

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> "Xaa" can be any amino acid

<400> 87

Gln Val Thr Glu Val Cys Ala Ala Thr Tyr Xaa Xaa Gly Xaa Glu Leu
1 5 10 15

Thr Phe Leu Asp Asp Ser Ile Cys Thr
20 25

<210> 88
<211> 25
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence 2

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(14)

<223> "Xaa" can be any amino acid

<400> 88

Gln Val Thr Glu Val Cys Ala Ala Cys Tyr Xaa Xaa Gly Xaa Glu Leu
1 5 10 15

Thr Phe Leu Asp Asp Ser Ile Cys Thr
20 25

<210> 89

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence from fusion protein

<400> 89

Cys Lys Val Glu Leu Met Tyr Pro Pro Pro Tyr Tyr Leu
1 5 10

<210> 90

<211> 27

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence from fusion protein

<400> 90

Cys Lys Val Asp Ser Thr Ile Tyr Ala Ser Tyr Tyr Glu Cys Gly His
1 5 10 15

Gly Leu Ser Thr Gly Gly Tyr Gly Tyr Asp Ser
20 25

<210> 91

<211> 18

<212> PRT

<213> Artificial Sequence

<220>

<223> sequence from fusion protein

<400> 91

Cys Lys Val Glu Ala Gly Cys Lys Asn Phe Phe Trp Lys Thr Phe Thr
1 5 10 15

Ser Cys

<210> 92
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein

<400> 92

Cys Lys Val Gly Trp Gly Leu Arg Gly Glu Glu Gly Asp Tyr Tyr Met
1 5 10 15

Asp Val

<210> 93
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> "Xaa" can be any amino acid

<220>


<221> MISC_FEATURE
<222> (8)..(8)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> "Xaa" can be any amino acid

 <220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> "Xaa" can be any amino acid

<400> 93

Cys Lys Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 94
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE

<222> (4)..(4)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (5)..(5)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> "Xaa" can be any amino acid

② | <220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (10)..(10)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (15)..(15)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (16)..(16)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (17)..(17)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (18)..(18)
<223> "Xaa" can be any amino acid

<400> 94

Cys Lys Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10 15

Xaa Xaa

<210> 95
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE
<222> (4)..(4)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE

<222> (5)..(5)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (6)..(6)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (8)..(8)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (9)..(9)
<223> "Xaa" can be any amino acid

Q/
<220>
<221> MISC_FEATURE
<222> (11)..(11)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(12)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (13)..(13)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (14)..(14)
<223> "Xaa" can be any amino acid

<400> 95

Cys Lys Val Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10

<210> 96
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE
<222> (4)..(10)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(15)
<223> "Xaa" can be any amino acid

<400> 96

Cys Lys Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15

<210> 97
<211> 17
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE
<222> (4)..(11)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (12)..(17)
<223> "Xaa" can be any amino acid

<400> 97

Cys Lys Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa
1 5 10 15

Xaa

<210> 98
<211> 21
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE
<222> (4)..(13)
<223> "Xaa" can be any amino acid

<220>
<221> MISC_FEATURE
<222> (15)..(21)
<223> "Xaa" can be any amino acid

<400> 98

Cys Lys Val Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa
1 5 10 15

Xaa Xaa Xaa Xaa Xaa
20

<210> 99
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE
<222> (5)..(13)
<223> "Xaa" can be any amino acid

<400> 99

Cys Lys Val Glu Xaa Xaa Xaa Xaa Xaa Xaa Xaa Xaa
1 5 10

<210> 100
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE
<222> (4)..(18)
<223> "Xaa" can be any amino acid

<400> 100

Cys Lys Val Glu Xaa Xaa Xaa Xaa Xaa Xaa Cys Xaa Xaa Xaa Xaa Xaa
1 5 10 15

Xaa Xaa

<210> 101
<211> 18
<212> PRT
<213> Artificial Sequence

<220>
<223> sequence from fusion protein containing the random sequence

<220>
<221> MISC_FEATURE
<222> (10)..(15)
<223> "Xaa" can be any amino acid

<400> 101

Cys Lys Val Glu Ala Gly Cys Lys Asn Xaa Xaa Xaa Xaa Xaa Thr
1 5 10 15

Ser Cys

<210> 102
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 102

Leu Pro Ser Ser Asp Thr Arg Ala Tyr Ser
1 5 10

<210> 103
<211> 8

<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR# inserts possessing randomly generated sequence

<400> 103

Gln Glu Ser Gly Gly Arg Pro Gly
1 5

<210> 104
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 104

Leu Pro Arg Gly Pro Pro Leu Leu Ser Leu
1 5 10

<210> 105
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 105

Ser Pro Gly Arg Cys Leu Asn
1 5

<210> 106
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<220>
<221> unsure
<222> (8)..(8)
<223> stop codon but Glu when expressed in Tg-1 or JM109 of E. col

<400> 106

Glu Trp Lys Arg Glu His Gly Gly

1

5

<210> 107
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 107

Leu Cys Pro Gly Ala Cys Gly Cys Val Tyr
1 5 10

<210> 108
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<220>
<221> unsure
<222> (4)..(4)
<223> stop codon but Glu when expressed in Tg-1 or JM109 strains of E.c
ol

<400> 108

Asn Ser Gly Glu Asn Glu Gly Gly
1 5

<210> 109
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 109

Asp Lys Pro Val Thr Lys Ser Gly
1 5

<210> 110
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<220>
<221> unsure
<222> (7)..(7)
<223> stop codon but Glu when expressed in Tg-1 or JM109 strains of E.c
ol

<400> 110

Ser Pro Gly Ala Cys Pro Glu
1 5

<210> 111
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 111

Ser Pro Gly Lys Cys Asp Gln
1 5

21
<210> 112
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 112

Ser Pro Gly Met Cys Ala Arg
1 5

<210> 113
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<220>
<221> unsure
<222> (8)..(8)
<223> stop codon but Glu when expressed in Tg-1 or JM109 strains of E.c
ol

<400> 113

Pro Phe Leu Phe Leu Pro Cys Glu Phe Phe Phe
1 5 10

<210> 114

<211> 11

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 114

Trp Thr Leu Gly His His Lys Leu Cys Glu Gly
1 5 10

<210> 115

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 115

Leu Phe Thr Cys Leu Leu Ala Leu Cys Ser
1 5 10

<210> 116

<211> 7

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 116

Ser Pro Gly Glu Cys Tyr Gly
1 5

<210> 117

<211> 13

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<220>
<221> MISC_FEATURE
<222> (7)..(7)
<223> "Xaa" can be any amino acid

<400> 117

Ser Trp Leu Ser Thr Thr Xaa Cys Leu Ser Ser Cys Ser
1 5 10

<210> 118
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<220>
<221> unsure
<222> (4)..(4)
<223> stop codon but Glu when expressed in Tg-1 or JM109 strains of E.c
ol

<400> 118

Ser Pro Gly Glu Cys Gln Asp
1 5

<210> 119
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 119

Leu Leu Gly Ser Leu Leu Ser Cys Phe Ala Ser Leu Ser
1 5 10

<210> 120
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generate sequence

<220>

<221> MISC_FEATURE
<222> (12)..(12)
<223> "Xaa" can be any amino acid

<400> 120

Ser Pro Gly Ser Leu Leu Ser Cys Phe Ala Ser Xaa Ser
1 5 10

<210> 121
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 121

Ser Pro Gly Arg Cys Thr Asp
1 5

<210> 122
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 122

Val Ile Cys His Ser Ser Val Cys Leu Ser Asp Val Cys
1 5 10

<210> 123
<211> 13
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 123

Val Ile Cys His Ser Ser Val Cys Leu Ser Glu Val Cys
1 5 10

<210> 124
<211> 10
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 124

Asp Leu Pro Ser Tyr Leu Ala Cys Ser Ile
1 5 10

<210> 125
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 125

Ser Pro Gly Arg Cys Asp Ala
1 5

<210> 126
<211> 14
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 126

Ala Leu Cys Trp Asp Val Phe Tyr Cys Ser Phe Pro Ser Tyr
1 5 10

<210> 127
<211> 11
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 127

Glu Leu Phe Gly His Ala Arg Tyr Cys Lys Gly
1 5 10

<210> 128
<211> 15
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<220>
<221> unsure
<222> (7)..(7)
<223> Stop codon but Glu when expressed in Tg-1 or JM109 strains of E.c
ol

<400> 128

Val Ser Ile Thr Ser Pro Glu Leu Cys Pro Val Lys Val Phe Asp
1 5 10 15

<210> 129
<211> 7
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

②/ <220>
<221> unsure
<222> (6)..(6)
<223> Stop codon but Glu when expressed in Tg-1 or JM109 strains of E.c
ol

<400> 129

Ser Pro Gly Lys Val Glu Asn
1 5

<210> 130
<211> 8
<212> PRT
<213> Artificial Sequence

<220>
<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 130

Leu Phe Val Pro Phe Val Ser Pro
1 5

<210> 131
<211> 7
<212> PRT
<213> Artificial Sequence

<220>

<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 131

Ser Pro Gly Asp Leu Trp Val
1 5

<210> 132

<211> 15

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 132

Glu Ser Gly Leu Ser Pro Val Ser Pro Cys Ser Leu Tyr Ser Leu
1 5 10 15

<210> 133

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 133

Thr Ser Ala Asn Gly Pro Tyr Gly
1 5

<210> 134

<211> 10

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 134

Pro Trp Ala Tyr Arg Phe Leu Ala Val Leu
1 5 10

<210> 135

<211> 8

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<223> V-like beta strand sequence

<400> 139

Ala Gly Phe Cys Cys
1 5

<210> 140

<211> 4

<212> PRT

<213> Homo Sapiens

<400> 140

Phe Trp Lys Thr
1

<210> 141

<211> 5

<212> PRT

<213> Homo Sapiens

<400> 141

Gly Phe Cys Cys Cys
1 5

<210> 142

<211> 6

<212> PRT

<213> Artificial Sequence

<220>

<223> CDR1 and CDR3 inserts possessing randomly generated sequence

<400> 142

Ser Pro Glu Cys Gln Asp
1 5



Creation date: 02-03-2004
Indexing Officer: HLE11 - LE HUNG
Team: OIPEBackFileIndexing
Dossier: 09623611

Legal Date: 08-13-2002

No.	Doccode	Number of pages
1	CRFL	5

Total number of pages: 5

Remarks:

Order of re-scan issued on